ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing
William E. Braun(Cleveland Clinic), Robert W. Schrier(University of Denver), Kaleab Z. Abebe(University of Pittsburgh), Franz T. Winklhofer(University of Kansas), Godela Brosnahan(University of Colorado Denver), Peter G. Czarnecki(Beth Israel Deaconess Medical Center), Frederic F. Rahbari-Oskoui(Emory University), Dana C. Miskulin(Tufts University), Vicente E. Torres(Mayo Clinic in Arizona), Charity G. Patterson(University of Pittsburgh), Michael F. Flessner, Ronald D. Perrone(Tufts Medical Center), Kyongtae T. Bae(University of Hong Kong), Theodore I. Steinman(Beth Israel Deaconess Medical Center), Marie C. Hogan(Mayo Clinic), Jared J. Grantham(National Institutes of Health), Arlene B. Chapman(Emory University), Peter C. Harris(Mayo Clinic)
Cited by 7
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
|Annals of Internal Medicine|2003|4.6k
Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia
|New England Journal of Medicine|2006|1.2k
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
Temporal relationships between hormonal and hemodynamic changes in early human pregnancy
|Kidney International|1998|535